These are called reverse transcriptase inhibitors, and there are two subclasses within this group--nucleoside reverse transcriptase inhibitors (NRTI) and
non-nucleoside reverse transcriptase inhibitors (NNRTI).
Agouron acquired the rights to develop and commercialize a second-generation
non-nucleoside reverse transcriptase inhibitor (NNRTI) from Shionogi & Co.
These guidelines include information about the use of abacavir ([Ziagen.sup.TM]) and the use of efavirenz ([Sustiva.sup.TM]), a
non-nucleoside reverse transcriptase inhibitor, for treating HIV infection in children.
- The US Food and Drug Administration has approved two new HIV-1 medicines: Delstrigo, a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg); and Pifeltro (doravirine, 100 mg), a new
non-nucleoside reverse transcriptase inhibitor (NNRTI) to be administered in combination with other antiretroviral medicines, US-based pharmaceutical company Merck (NYSE: MRK) said.
Rilpivirine is a
non-nucleoside reverse transcriptase inhibitor and is presently being marketed as Edurant, while dolutegravir is an integrase inhibitor marketed as Tivicay.
has entered into a license and collaboration agreement with Tibotec Pharmaceuticals for the development and commercialization of a once-daily, fixed-dose antiretroviral regimen containing Gilead's Truvada (emtricitabine and tenofovir disoproxil fumarate) and Tibotec's investigational
non-nucleoside reverse transcriptase inhibitor (NNRTI) TMC278 (rilpivirine hydrochloride, 25 mg) for treatment-naive HIV-infected individuals.
This is the first anti-HIV drug in the class called
non-nucleoside reverse transcriptase inhibitor (NNRTI).
In December, Bristol-Myers Squibb and Gilead Sciences announced that they will work together to develop a fixed-dose combination of Sustiva, a
non-nucleoside reverse transcriptase inhibitor ("non-nuke"), and Truvada, a combination pill containing the nucleoside reverse transcriptase inhibitor ("nuke") Emtriva and the nucleotide reverse transcriptase inhibitor Viread.
Other factors associated with severe hepatotoxicity in this study were use of nevirapine-containing drugs, which were associated in those taking a
non-nucleoside reverse transcriptase inhibitor with both early (OR 4.00) and late (OR 3.38) severe hepatotoxicity.
Another new anti-HIV drug in the
non-nucleoside reverse transcriptase inhibitor (NNRTI) class that has shown promise ("Full Pipeline: Success of experimental AIDS drugs offers promise of future therapies," SN: 2/22/03, p.
Sustiva (efavirenz; formerly called DMP-266) is a new
non-nucleoside reverse transcriptase inhibitor from DuPont Merck.